Role of morphine's metabolites in analgesia: Concepts and controversies

AAPS Journal

Volumn 8, Issue 2, 2006, Pages

  Wittwer, Erica ^a   Kern, Steven E ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical covariates; Clinical pharmacology; Morphine; Morphine 6 glucuronide

Indexed keywords

DIAMORPHINE; DRUG METABOLITE; GLUCOSE TRANSPORTER 1; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; MELANOCORTIN 1 RECEPTOR; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 3; OPIATE RECEPTOR; PLACEBO;

AGE; AMERICAN INDIAN; ANALGESIA; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CAUCASIAN; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG UTILIZATION; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HEROIN DEPENDENCE; HUMAN; JOINT PROSTHESIS; LIVER HOMOGENATE; MOUSE; NAUSEA; NONHUMAN; PAIN ASSESSMENT; POSTOPERATIVE PAIN; RAT; RESPIRATION DEPRESSION; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME;

AGING; ANALGESIA; ANIMALS; BIOTRANSFORMATION; FEMALE; GLUCURONIDES; HUMANS; MALE; MORPHINE; MORPHINE DERIVATIVES;

EID: 33744936323     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080239     Document Type: Review

References (40)

1. Coffman B, King C, Rios G, Tephly T. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos. 1998;26:73-77.
2. Ratka A, Wittwer E, Baker L, Kern S. Pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in healthy older men and women. Am J Pain Manage. 2004;14:45-55.
3. Stone A, Mackenzie P, Galetin A, Houston J, Miners J. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos. 2003;31:1086-1089.
4. Aasmundstad T, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17:347-352.
5. Faura C, Collins S, Moore R, McQuay H. Systematic review of factors affecting the ratio of morphine and its major metabolites. Pain. 1998;74:43-53.
6. Antonilli L, Suriano C, Paolone G, Badiani A, Nencini P. Repeated exposures to heroin and/or cadmium alter the rate of formation of morphine glucuronides in the rat. J Pharmacol Exp Ther. 2003;307:651-660.
7. Antonilli L, Semeraro F, Suriano C, Signore L, Nencini P. High levels of morphine-6-glucuronide in street heroin addicts. Psychopharmacology (Berl). 2003;170:200-204.
8. Lotsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet. 2001;40:485-499.
9. Smith G, Smith M. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain. 1995;62:51-60.
10. Vaughan CW, Connor M. In search of a role for the morphine metabolite morphine-3-glucuronide. Anesth Analg. 2003;97:311-312.
11. Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage. 2003;25:74-91.
12. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage. 1997;14:157-167.
13. Baker L, Hyrien O, Ratka A. Contributions of morphine-3-glucuronide and morphine-6-glucuronide to differences in morphine analgesia in humans. Am J Pain Manage. 2003;13:16-28.
14. Hemstapat K, Monteith G, Smith D, Smith M. Morphine-3-glucuronide's neuro-excitatory effects are mediated by indirect activation of NMDA receptors: mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg. 2003;97:494-505.
15. Okura T, Saito M, Nakanishi M, et al. Different distribution of morphine and morphine-6β-glucuronide after intracerebroventricular injection in rats. Br J Pharmacol. 2003;140:211-217.
16. Mantione KJ, Goumon Y, Esch T, Stefano GB. Morphine 6B glucuronide: fortuitous morphine metabolite or preferred peripheral regulatory opiate? Med Sci Monit. 2005;11:MS43-MS46.
17. Lotsch J, Skarke C, Darimont J, Schmidt H, Geisslinger G. The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology. 2001;95:1329-1338.
18. Tunblad K, Hammarlund-Udenaes M, Jonsson EN. Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. Eur J Pharm Sci. 2005;24:49-57.
19. Bouw MRXR, Tunblad K, Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats - pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol. 2001;134:1796-1804.
20. Bourasset F, Cisternino S, Temsamani J, Scherrmann JM. Evidence for an active transport of morphine-6-β-D-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J Neurochem. 2003;86:1564-1567.
21. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics. Clin Pharmacokinet. 2004;43:983-1013.
22. Buetler TMW, Wilder-Smith OH, Wilder-Smith CH, Aebi S, Cerny T, Brenneisen R. Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers. Br J Anaesth. 2000;84:97-99.
23. Hanna MHEK, Fung M. Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery. Anesthesiology. 2005;102:815-821.
24. Motamed C, Mazoit X, Ghanouchi K, et al. Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief. Anesthesiology. 2000;92:355-360.
25. Langlade A, Carr DB, Serrie A, Silbert BS, Szyfelbein SK, Lipkowski AW. Enhanced potency of intravenous, but not intrathecal, morphine and morphine-6-glucuronide after burn trauma. Life Sci. 1994;54:1699-1709.
26. Grace D, Fee J. A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg. 1996;83:1055-1059.
27. Yamada H, Ishii K, Ishii Y, et al. Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci. 2003;28:395-401.
28. Cann C, Curran J, Milner T, Ho B. Unwanted effects of morphine-6-glucuronide and morphine. Anaesthesia. 2002;57:1200-1203.
29. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology. 2003;99:788-798.
30. Kilpatrick G, Smith T. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005;25:521-544.
31. Pasternak G. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001;22:67-70.
32. Rossi GC, Pan YX, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett. 1995;369:192-196.
33. Rossi GC, Leventhal L, Pan YX, et al. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception. J Pharmacol Exp Ther. 1997;281:109-114.
34. Zelcer N, Wetering K, Hillebrand M, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA. 2005;102:7274-7279.
35. Lotsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology. 2002;97:814-819.
36. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreased the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002;12:3-9.
37. Romberg R, Olofsen E, Bijl H, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102:522-530.
38. Mogil JSSS, Strasburg K, Kaplan L, et al. Melanocortin-1 receptor gene variants affect pain and μ-opioid analgesia in mice and humans. J Med Genet. 2005;42:583-587.
39. Wittwer E, Ratka A, Kern S. The impact of endogenous steroidal hormones on the pharmacokinetics of oral morphine: a population analysis. Proceedings of the 79th IARS Clinical and Scientific Conference. 79th IARS Clinical and Scientific Conference; March 20-22, 2005; Honolulu, HI. Philadelphia, PA: LWW Publishers; 2004: PR04-R58.
40. Murthy BR, Pollack GM, Brouwer KL. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol. 2002;42:569-576.